BPC-157 and TB-500, examined separately

BPC-157 and TB-500 turn up together constantly in injury-recovery corners of the internet, almost always discussed as a pair rather than as two separate substances. They are not the same molecule, and they do not come from the same research tradition. BPC-157 is a synthetic 15-amino-acid pentadecapeptide (a short chain of 15 amino acids) modeled on a sequence found in human gastric juice^[4]. TB-500 is a grey-market name most often used for a fragment of thymosin beta-4, a naturally occurring protein involved in cell movement and tissue repair^[3]. Neither is approved by the FDA as a medicine, and neither has completed a human trial for the injury-recovery uses that drive most of the online interest in them. Both currently sit inside a separate FDA process reviewing which unapproved peptides compounding pharmacies may legally prepare^[1]. Below is what the animal literature actually reports about each peptide on its own, where the regulatory picture stands, and why we are not going to evaluate any protocol for combining them: nobody has published the human safety data that would make that an answerable question yet.

What BPC-157 is

BPC-157, short for Body Protection Compound 157, was first described by researchers at the University of Zagreb, who isolated it from human gastric juice in the early 1990s. The literature calls it a 'stable gastric pentadecapeptide,' meaning a 15-amino-acid chain that holds together in the digestive tract better than most peptides do^[4]. The rodent literature on BPC-157 is extensive and mostly positive: studies report faster healing of transected Achilles tendons, ligament injuries, and gut lesions, alongside effects on blood-vessel growth (angiogenesis, the formation of new blood vessels) and growth-factor signalling that would plausibly explain those results. A 2025 review in the journal Pharmaceuticals extended the same preclinical pattern into corneal healing, reporting that BPC-157 normalized elevated eye pressure and preserved tissue structure in rat models^[4]. What that body of work does not include is a completed human trial. A 2026 review in the American Journal of Sports Medicine, written for orthopaedic and sports-medicine physicians, found that the human benefit claimed for BPC-157 rests on a single case series that the review's own authors describe as having significant methodological flaws and no control group^[2].

What TB-500 (the thymosin beta-4 fragment) is

TB-500 is a trickier label than BPC-157 because it does not correspond to a single molecule. Vendors use the name for a short synthetic fragment that mimics part of thymosin beta-4, and sometimes for full-length thymosin beta-4 itself, a naturally occurring 43-amino-acid protein that regulates actin, the structural protein cells use to move and rebuild themselves^[3]. The foundational 2005 review of thymosin beta-4's repair biology, by Allan Goldstein and colleagues, describes it as the major actin-binding molecule in mammalian cells and lays out preclinical evidence for its role in wound, cardiac, and nerve repair^[3]. That preclinical case is substantial. The human trial record is much narrower, and it sits almost entirely outside the injury-recovery use case the grey market sells TB-500 for: the closest thing to completed late-stage human data is a topical thymosin beta-4 eye-drop formulation tested for a specific eye condition, not an injectable product aimed at tendons or muscle. The 2026 orthopaedic review already cited above is direct about the gap for that injectable use: human orthopaedic data 'are lacking,' and both BPC-157 and TB-500 remain banned substances in competitive sport^[2].

Where the regulatory picture stands

Neither peptide is an approved medicine in the United States. Both are instead moving through a narrower FDA process: the Pharmacy Compounding Advisory Committee met on 23 and 24 July 2026 to consider BPC-157 (free base and acetate) and TB-500 (free base and acetate) for the section 503A bulk drug substances list, the list that governs which unapproved ingredients a compounding pharmacy may legally prepare into a prescription product^[1]. Being nominated for that list is not the same as being approved. It is a compounding-specific question, and the committee's role is to advise the FDA on what pharmacists may prepare, not to grant marketing authorization to anyone. Outside that process, both peptides are sold online as unlabelled 'research chemicals,' a label that does not make human use legal and does not put the product through any pharmaceutical quality control. The Department of Defense's Operation Supplement Safety programme names BPC-157 specifically as an unapproved drug and warns service members away from it regardless of how a vendor labels the vial^[5]. Both compounds are also barred in competitive sport under anti-doping rules that treat them as prohibited substances^[2]. The country-by-country detail for each, where it exists, is on our BPC-157 page and our TB-500 page.

What we don't yet know

The honest state of the evidence, for both peptides, is that the animal data is far more developed than the human data. We do not know whether the rodent tendon, gut, or tissue-repair findings for either compound hold up in people at any dose. We do not know a validated human safety profile for chronic use of either one on its own. And there is no published research, of any kind, on using the two together^[2]. If you have come across dosing or timing recommendations for combining BPC-157 and TB-500, including in online communities, those come from individual user experience rather than a clinical trial or a regulator, and we are not going to add our own protocol to that pile. If you are considering either compound, that decision, and any question about combining substances, belongs with a clinician who knows your medical history, not with an internet thread.